Lacosamide

Lacosamide

SCHEMBL35330

COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Lacosamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A known ✓ Q15858 1/20 1.00
CA12 O43570 1/20 1.00
CA1 P00915 1/20 1.00
CA2 P00918 1/20 1.00
CA3 P07451 1/20 1.00
CA4 P22748 1/20 1.00
CA6 P23280 1/20 1.00
CA5A P35218 1/20 1.00
CA7 P43166 1/20 1.00
CACNA1C Q13936 1/20 1.00
CA9 Q16790 1/20 1.00
CA13 Q8N1Q1 1/20 1.00
CA14 Q9ULX7 1/20 1.00
CA5B Q9Y2D0 1/20 1.00
ALDH1A1 P00352 1/20 0.56
CTSS P25774 1/20 0.55
CTSK P43235 1/20 0.55
EGFR P00533 1/20 0.54
SRC P12931 1/20 0.54
ATM Q13315 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lacosamide SCHEMBL225889 1.00 CA12 (1.00) CA12CA1CA2CA3CA4
Lacosamide SCHEMBL223961 1.00 CA12 (1.00) CA12CA1CA2CA3CA4
Lacosamide SCHEMBL28184085 0.99 CA12 (0.97) CA12CA1CA2CA3CA4
SCHEMBL8601669 0.97 CA12 (0.94) CA12CA1CA2CA3CA4
SCHEMBL12188319 0.93 CA12 (0.87) CA12CA1CA2CA3CA4
SCHEMBL24081395 0.90 CA1 (0.82) CA12CA1CA2CA3CA4
Lacosamide SCHEMBL12210097 0.90 CA12 (0.82) CA12CA1CA2CA3CA4
SCHEMBL527808 0.90 CA12 (0.81) CA12CA1CA2CA3CA4
SCHEMBL14931211 0.90 CA12 (0.81) CA12CA1CA2CA3CA4
SCHEMBL12168548 0.90 CA12 (0.81) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7733 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
US-20260137654-A1 COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER THE REGENTS OF THE UNIV OF CALIFORNIA (US) 2026-05-21 US claimed
CN-122031409-A Lacosamide sustained-release micro-tablet and preparation method thereof 山东丰金生物医药有限公司 2026-05-15 CN claimed
US-20260124211-A1 COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) 2026-05-07 US claimed
EP-4736841-A1 A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT IQ medical GmbH (DE) 2026-05-06 EP claimed
US-20260115161-A1 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN LAMINAR PHARMACEUTICALS S A (ES) 2026-04-30 US claimed
US-12595237-B2 Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) 2026-04-07 US claimed
US-12594256-B2 A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy ANAVEX LIFE SCIENCES CORP. (US) 2026-04-07 US claimed
EP-4288042-B1 COMBINATION THERAPY FOR TREATING EXECUTIVE FUNCTION DISORDERS ANAKA PHARMACEUTICALS INC (US) 2026-04-01 EP claimed
US-20260083706-A1 5HT AGONISTS FOR TREATING DISORDERS UNIV CALIFORNIA (US) 2026-03-26 US claimed
EP-1373300-A2 NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN SCHWARZ PHARMA AG (DE) 2004-01-02 EP claimed
US-20030171300-A1 Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary UCB PHARMA GMBH (DE) 2003-09-11 US claimed
EP-1243263-B1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain SANOL ARZNEI SCHWARZ GMBH (DE) 2002-11-27 EP claimed
EP-0996435-B1 AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE RES CORP TECHNOLOGIES INC (US) 2002-10-02 EP claimed
WO-2002074297-A1 NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING ALLODYNIA OR OTHER DIFFERENT TYPES OF CHRONIC OR PHANTOM PAIN SCHWARZ PHARMA AG (DE) 2002-09-26 WO claimed
WO-2002074784-A2 NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN SCHWARZ PHARMA AG (DE) 2002-09-26 WO claimed
EP-1243262-A1 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain SCHWARZ PHARMA AG (DE) 2002-09-25 EP claimed
EP-1243263-A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain SCHWARZ PHARMA AG (DE) 2002-09-25 EP claimed
EP-0888289-B1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES RES CORP TECHNOLOGIES INC (US) 2001-06-13 EP claimed
US-6133261-A THERAPEUTIC METHOD FOR TREATING OR PREVENTING STROKE AND OTHER ISCHEMIC DISORDERS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2000-10-17 US claimed